NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

5734.50 145.20 (2.60%)

57.50% Gain from 52W Low

650.6K NSE+BSE Volume

NSE 15 Apr, 2025 3:31 PM (IST)

152,233

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

25 Mar 2025

5734.50

2.60%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Number of FII/FPI investors increased from 723 to 826 in Dec 2024 qtr.

Divi's Laboratories Ltd.

05 Feb 2025

5734.50

2.60%

High value projects will sustain growth in Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.

Divi's Laboratories Ltd. has gained 51.72% in the last 1 Year

Divi's Laboratories Ltd.

04 Feb 2025

5734.50

2.60%

DIVI'S LABORATORIES

Accumulate: Divi's Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Divi's Laboratories Ltd. is trading above its 200 day SMA of 5529.0

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

Custom synthesis drives earnings; generics stable QoQ

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower tax rate (due to the shift to a new tax regime).

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

03 Feb 2025

5734.50

2.60%

Divis Labs (HOLD): Back to higher growth trajectory

Hold: Divi's Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Q3 sales/EBITDA/PAT were 0.6%/7.5%/22.3% above our estimates. PAT was higher than estimated due to the adoption of the new tax regime

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

11 Nov 2024

5734.50

2.60%

Multiple growth levers to drive Custom Synthesis segment

Accumulate: Divi's Laboratories Ltd.

Target

KRChoksey

Divis Lab revenue beat our estimates significantly due to strong growth in the Custom Synthesis segment. EBITDA beat our estimate due to lower-than-expected other expenses and employee expenses.

Divi's Laboratories Ltd. is trading above its 200 day SMA of 5529.0

Divi's Laboratories Ltd.

11 Nov 2024

5734.50

2.60%

Company set for continued growth

Buy: Divi's Laboratories Ltd.

Recommendation Target

Sharekhan

Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates.

Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.

Divi's Laboratories Ltd.

10 Nov 2024

5734.50

2.60%

Divi's Labs (SELL): Healthy Q2; rich valuations

Sell: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

DIVI reported healthy 2QFY25 earnings which was a beat on our estimates. Exports contributed 87% of sales and the US 71%

Divi's Laboratories Ltd.'s price crossed above 30Day SMA today

Divi's Laboratories Ltd.

07 Aug 2024

5734.50

2.60%

Ramp up in custom synthesis and new generic APIs to drive margins

Hold: Divi's Laboratories Ltd.

Target

KRChoksey

DIVISLAB continues to post results below estimates due to continued weakness in generic pricing. We hence cut down our EPS estimates by 3% each for FY25E/FY26E.